Key facts
- Infinitopes’s last known valuation is $28.4M (Dec 2022).
- It has raised $49.4M; the latest was Seed Round ($37.9M) in Jan 2026.
- Notable investors include Innovate UK, Octopus Ventures, Caffeinated Capital, University of Oxford, Amplify Partners — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Infinitopes
- ·The full record, as it builds
Funding rounds
No funding rounds for Infinitopes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Infinitopes
Operator of a cancer research company intended for the immune system to prevent metastases and save lives. The company offers a platform that identifies tumor-specific peptides with high accuracy and delivers them via a durable viral vector, enabling oncologists to provide post-surgical relapse prevention for oesophageal cancer patients, ultimately advancing earlier and smarter immunotherapy.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2021
- Employees
- 20
- Website
- infinitopes.com/
- Ownership
- Privately Held (backing)
Infinitopes doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Infinitopes shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Infinitopes in its N-PORT filings yet. We sweep new filings monthly.